Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $52.2 million.

  • Stoke Therapeutics' Total Liabilities fell 1478.12% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year decrease of 1478.12%. This contributed to the annual value of $42.5 million for FY2024, which is 3815.67% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Total Liabilities of $52.2 million as of Q3 2025, which was down 1478.12% from $49.6 million recorded in Q2 2025.
  • Stoke Therapeutics' Total Liabilities' 5-year high stood at $77.1 million during Q2 2022, with a 5-year trough of $42.5 million in Q4 2024.
  • Moreover, its 4-year median value for Total Liabilities was $66.7 million (2023), whereas its average is $64.0 million.
  • Data for Stoke Therapeutics' Total Liabilities shows a peak YoY increase of 251.18% (in 2024) and a maximum YoY decrease of 3815.67% (in 2024) over the last 5 years.
  • Over the past 4 years, Stoke Therapeutics' Total Liabilities (Quarter) stood at $71.2 million in 2022, then dropped by 3.43% to $68.8 million in 2023, then plummeted by 38.16% to $42.5 million in 2024, then increased by 22.63% to $52.2 million in 2025.
  • Its Total Liabilities stands at $52.2 million for Q3 2025, versus $49.6 million for Q2 2025 and $56.8 million for Q1 2025.